Novel immunosuppressive agents in kidney transplantation

doi:10.5500/wjt.v3.i4.68

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 3, Issue 4

This Article

Academic Content and Language Evaluation of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (7639)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Tables (1-3) series.

Item

Count

PDF

632

WORD

321

HTML

4783

Tables (1-3)

458

Sum=6194

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

722

Download

723

Sum=1445

Dec 24, 2013 (publication date) through Nov 23, 2024

Times Cited of This Article

Times Cited (37)

Journal Information of This Article

Publication Name

World Journal of Transplantation

ISSN

2220-3230

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Review

World J Transplant. Dec 24, 2013; 3(4): 68-77
Published online Dec 24, 2013. doi: 10.5500/wjt.v3.i4.68

Table 3 Clinical trials

Agent	Identifier	Study name	Start date
ASKP1240	NCT01780844	A Study to Assess the Efficacy and Safety of ASKP1240 in de Novo Kidney Transplant Recipients	February 2013
Voclosporin	NCT01586845	Safety and Efficacy Study of Voclosporin and Tacrolimus in Transplantation	March 2013
Prolonged Release Tacrolimus	NCT01294020	Study to Compare the Pharmacokinetics of Tacrolimus in Stable Pediatric Allograft Recipients Converted From Prograf^® to Advagraf^®	May 2011
Bortezomib	NCT01873157	Bortezomib in Late Antibody-mediated Kidney Transplant Rejection (BORTEJECT)	October 2013
	NCT01349595	Impact of Proteasome Inhibition on Anti-Donor HLA Antibody Production After Kidney Transplantation	December 2011
	NCT01842074	Desensitization With Bortezomib Before a Living Kidney Donation (VELDON)	January 2013
	NCT01502267	Desensitization Protocol for Highly Sensitized Patients on the Waiting List for Kidney Transplant	January 2010
	NCT00722722	The Impact of Velcade on Antibody Secreting Cells in Sensitized Renal Allograft Candidates	June 2008
Eculizumab	NCT01349595	Impact of Proteasome Inhibition on Anti-Donor HLA Antibody Production After Kidney Transplantation	December 2011
	NCT01327573	Eculizumab Therapy for Chronic Complement-Mediated Injury in Kidney Transplantation	March 2011
	NCT01095887	Eculizumab Added to Conventional Treatment in the Prevention of Antibody-mediated Rejection in ABO Blood Group Incompatible Living Donor Kidney Transplantation (ABOi)	March 2010
	NCT01403389	A Study of the Activity of Eculizumab for Prevention of Delayed Graft Function In Deceased Donor Kidney Transplant	August 2011
	NCT01567085	Safety and Efficacy Of Eculizumab In The Prevention Of Antibody Mediated Rejection (AMR) In Sensitized Recipients Of A Kidney Transplant From A Deceased Donor	May 2012
	NCT01106027	Dosing Regimen of Eculizumab Added to Conventional Treatment in Positive Crossmatch Deceased Donor Kidney Transplant	March 2010
	NCT01399593	Safety and Efficacy of Eculizumab to Prevent AMR in Living Donor Kidney Transplant Recipients Requiring Desensitization	September 2011

Citation: Hardinger KL, Brennan DC. Novel immunosuppressive agents in kidney transplantation. World J Transplant 2013; 3(4): 68-77
URL: https://www.wjgnet.com/2220-3230/full/v3/i4/68.htm
DOI: https://dx.doi.org/10.5500/wjt.v3.i4.68